# Assessing PA-824 for Tuberculosis (the APT Trial)

> **NCT02256696** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 157 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** PA-824
- **DRUG:** Rifampin
- **DRUG:** Rifabutin
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT02256696
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-29
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256696, "Assessing PA-824 for Tuberculosis (the APT Trial)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02256696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*